07:23 AM EDT, 09/08/2025 (MT Newswires) -- Eli Lilly ( LLY ) said Monday that topline results from its phase 3 trial evaluating Jaypirca showed clinically meaningful improvement in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma without 17p deletions.

Jaypirca significantly improved progression-free survival compared to chemoimmunotherapy in treatment-naive patients, the company said.

Eli Lilly ( LLY ) added overall survival results were not yet mature but were in favor of Jaypirca.